Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $5.862 million which beat the analyst consensus estimate of $5.733 million by 2.24 percent. This is a 53.85 percent decrease over sales of $12.702 million the same period last year.